source
- STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’In this edition of STAT Health Tech: Hims earnings, Omada's PBM strategy, and the uphill battle faced by new sepsis algorithms.STAT · 3mo ago↗ source
- STAT+: Hims’ sales miss as telehealth competition growsBristol's partnership with Hengrui Pharma, Viiv loses HIV treatment case, and more biotech news from The ReadoutSTAT · 3mo ago↗ source
- Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence RiskA Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.onclive · 3mo ago↗ source